Send to

Choose Destination
Acta Ophthalmol Scand. 2003 Dec;81(6):648-52.

Intravitreal triamcinolone acetonide for the treatment of chronic pseudophakic cystoid macular oedema.

Author information

Istanbul Retina Institute, Istanbul, Turkey.



To evaluate the effect of intravitreal triamcinolone acetonide for chronic pseudophakic cystoid macular oedema (CME) resistant to medical treatment.


Six eyes of six patients with chronic pseudophakic CME, aged 58-74 years (average 66 years), made up the study population. All eyes had persistent CME despite having received medical treatment for at least 3 months. Intravitreal injection of 4 mg (0.1 ml) triamcinolone acetonide was offered to treat macular oedema. The visual and anatomic responses were observed as well as potential complications related to the injection procedure and corticosteroid medication.


The follow-up period was between 6 and 10 months (mean 8.5 months). Baseline central macular thickness averaged 504 microm. At 1 month, a reduction in the mean central macular thickness of 52% from 504 microm to 264 microm was obtained. At 3 and 6 months, the mean central macular thicknesses were 240 microm and 232 microm, respectively. Five of the six eyes maintained a visual gain of 15 or more letters from baseline at 6 months. During follow-up no patient had intraocular pressure (IOP) exceeding 21 mmHg. No injection-related complications were encountered.


Intravitreal triamcinolone acetonide is a promising therapeutic method for chronic pseudophakic CME resistant to medical treatment. Further study with a longer follow-up period and larger series is warranted to assess the treatment's longterm efficacy and safety and the need for retreatment.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center